Abiraterone acetate - Johnson & Johnson

Drug Profile

Abiraterone acetate - Johnson & Johnson

Alternative Names: Aviraterone acetate; CB-7630; JNJ-212082; Zaitiga; Zaytiga; Zitiga; Zytiga

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator The Institute of Cancer Research
  • Developer All Ireland Cooperative Oncology Research Group; Cancer Research UK; Cougar Biotechnology; Janssen Research & Development; Johnson & Johnson; UNICANCER
  • Class Androstenols; Antiandrogens; Antineoplastics; Small molecules
  • Mechanism of Action CYP17A1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Prostate cancer
  • Phase II Breast cancer; Ovarian cancer
  • No development reported Congenital adrenal hyperplasia

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Congenital-adrenal-hyperplasia in USA (PO, Suspension)
  • 13 Oct 2017 Janssen initiates enrolment in a phase II trial in Prostate cancer (Second-line therapy or greater, Combination therapy) in USA (PO) (NCT03279250)
  • 13 Oct 2017 Committee for Medicinal Products for Human Use recommends approval of a Type II variation application for abiraterone acetate for Prostate cancer (Combination therapy, Metastatic disease, Newly-diagnosed) in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top